Alterity Therapeutics Limited
ATH
Rank in Stocks
#26008
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997,... Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Share Price
$0.1904269
Market Cap
$41.61M
Change (1 day)
-3.57%
Change (1 year)
-45.59%
Country
AU
Trade Alterity Therapeutics Limited (ATH)
Category
Healthcare
P/E ratio for Alterity Therapeutics Limited (ATH)
P/E ratio as of 2026 TTM: 0
According to Alterity Therapeutics Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Alterity Therapeutics Limited from 2026 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | - |
US
|
|
| -28.36 | - |
US
|
|
| -24.57 | - |
AU
|
|
| - | - |
CH
|
|
| 30.33 | - |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.